Therapeutic taping in patients with diabetic peripheral neuropathy

Effectiveness of Neuromuscular Taping on Balance, Proprioception, Pain and Nerve Conduction parameters in patients with Diabetic Peripheral Neuropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/049324

Enrollment

Registered

2023-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: EXPERIMENTAL GROUP: Experimental group will receive Neuromuscular Taping (NMT) and Transcutaneous Electrical Nerve Stimulation (TENS). given 3 times a week for 8 weeks (24 sessions).N

Eligibility

Inclusion criteria

Inclusion criteria: 1. Referred cases of Type 1 & Type 2 diabetes mellitus induced diabetic peripheral neuropathy of lower limbs diagnosed by physician and score more than 2/13 on MNSI physical appearance section and scored greater than 1/10 on physical examination of Michigan neuropathy screening instrument (MNSI) 2. Diabetes duration: >=5 years 3. Age between 40 to 70 years 4.Chronic symmetric sensorimotor involvement of bilateral lower limb after excluding all other causes of peripheral neuropathies 5. Leeds Assessment of Neuropathic Symptoms Scale (LANSS) score > 12 6.Berg Balance Scale (BBS) 7. HbA1C report >=6% not older than 3 months 8. Willing to participate 9. BMI <30kg/m2 (According to Asian criterion)

Exclusion criteria

Exclusion criteria: 1. Allergic to tape 2. Any other diagnosed neuromuscular disease 3. Vestibular system dysfunction in the last one year (complaint of dizziness, vertigo, nausea and loss of balance) 4.Diabetic foot ulcers, neuropathic joint, charcot joint 5. . History of any recent injury (soft tissue and bony) in lower limb six months prior to participation in study 6. Patients with rheumatoid arthritis 7. Patients with varicose veins 8. Any other cause of balance and gait disturbance 9. Deformities of lower limb 10. Patients with leg length discrepancy

Design outcomes

Primary

Measure	Time frame
1. Berg Balance Scale (BBS) 2. PedaloÂ®-Sensamove Balance Test Pro with Miniboard 3. Leeds Assessment of Neuropathic Symptoms and Signs(LANSS)Pain Scale 4.Nerve Conduction Velocity (NCV) 5. Michigan Neuropathy Screening InstrumentTimepoint: 1. Berg Balance Scale (BBS) 2. PedaloÂ®-Sensamove Balance Test Pro with Miniboard 3. Leeds Assessment of Neuropathic Symptoms and Signs(LANSS)Pain Scale 4.Nerve Conduction Velocity (NCV) 5. Michigan Neuropathy Screening Instrument	—

Measure

Time frame

1. Berg Balance Scale (BBS) 2. PedaloÂ®-Sensamove Balance Test Pro with Miniboard 3. Leeds Assessment of Neuropathic Symptoms and Signs(LANSS)Pain Scale 4.Nerve Conduction Velocity (NCV) 5. Michigan Neuropathy Screening InstrumentTimepoint: 1. Berg Balance Scale (BBS) 2. PedaloÂ®-Sensamove Balance Test Pro with Miniboard 3. Leeds Assessment of Neuropathic Symptoms and Signs(LANSS)Pain Scale 4.Nerve Conduction Velocity (NCV) 5. Michigan Neuropathy Screening Instrument

—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactProf Dr Manu Goyal

MAHARISHI MARKANDESHWAR INSTITUTE OF PHYSIOTHERAPY AND REHABILITATION, MM (DU)

manugoyal1111@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026